Real-world study on characteristics of advanced melanoma patients with sustained complete response (CR) after elective 1st line anti-programmed death-1 (anti-PD1) monotherapy discontinuation.

被引：0

作者：

Ochenduszko, Sebastian

Garcia, Javier

Juan-Fita, Maria Jose

Gonzalez-Barrallo, Ines

Colomina, Julio Herrero

Beveridge, Robert Diaz

Martinez, Silverio Ros

Lafuente, Blanca Sanchez

Tomas, Alberto Jacobo Cunquero

Berrocal, Alfonso

Cerezuela-Fuentes, Pablo

Fra, Pablo Luna

Peeters, Alicia Gervas

Gonzalez, Jose Luis Sanchez

Garcia, Andres Meana

Garcia, Mariasun Algarra

Garcia, Eugenio Palomares

Altozano, Javier Perez

Guerola, Monica Tallon

Maestu, Inmaculada

机构：

[1] Hosp Univ Dr Peset, Valencia, Spain

[2] Hosp Ctr Tourcoing, Tourcoing, France

[3] Inst Valenciano Oncol, Valencia, Spain

[4] Hosp Clin Univ Valencia, INCLIVA, Valencia, Spain

[5] Unidad Canc Gipuzkoa, OSID Onkol, San Sebastian, Spain

[6] Hosp Univ Politecn La Fe, Valencia, Spain

[7] Hosp Clin Univ Virgen Arrixaca, Murcia, Spain

[8] Hosp Gen Univ Valencia, Valencia, Spain

[9] Hosp Gen Univ Valencia, Med Oncol, Valencia, Spain

[10] Hosp Univ Son Espases, Palma de Mallorca, Spain

[11] Hosp Univ Doctor Peset, Valencia, Spain

[12] Hosp Gen Univ Alicante, Alicante, Spain

[13] Hosp Marina Baixa, Villajoyosa, Spain

[14] Hosp Univ Vinalopo, Elche, Spain

[15] Hosp Virgen Los Lirios, Alcoy, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e21529

引用

页数：1

共 50 条

[41] Real-world efficacy of anti-PD-1 antibodies in advanced acral melanoma patients: A retrospective, multicenter study (JAMP study).
Nakamura, Yasuhiro
Namikawa, Kenjiro
Yoshino, Koji
Yoshikawa, Shusuke
Uchi, Hiroshi
Goto, Katsunobu
Nakamura, Yoshiyuki
Fukushima, Satoshi
Kiniwa, Yukiko
Takenouchi, Tatsuya
Uhara, Hisashi
Kawai, Toru
Hatta, Naohito
Funakoshi, Takeru
Teramoto, Yukiko
Otsuka, Atsushi
Doi, Haruki
Ogata, Dai
Matsushita, Shigeto
Yamazaki, Naoya
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[42] Comparison of Efficacy and Safety of Anti-Programmed Cell Death-1 Antibody Plus Lenvatinib and Chemotherapy as First-Line Therapy for Patients with Stage IV Gallbladder Cancer: A Real-World Study in a Chinese Population
Wu, Tiantian
Pu, Changsheng
Wang, Qiang
Zhang, Keming
BIOMEDICINES, 2023, 11 (11)
[43] First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.
Gettinger, Scott N.
Hellmann, Matthew David
Shepherd, Frances A.
Antonia, Scott Joseph
Brahmer, Julie R.
Chow, Laura Quan Man
Goldman, Jonathan Wade
Juergens, Rosalyn A.
Borghaei, Hossein
Ready, Neal
Gerber, David E.
Nathan, Faith Ellen
Shen, Yun
Harbison, Christopher
Rizvi, Naiyer A.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[44] Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy
Sandhu, Shahneen
Atkinson, Victoria
Cao, Maria Gonzalez
Medina, Theresa
Rivas, Ainara Soria
Menzies, Alexander M.
Caro, Ivor
Roberts, Louise
Song, Yuyao
Yan, Yibing
Guo, Yu
Xue, Cloris
Long, Georgina V.
EUROPEAN JOURNAL OF CANCER, 2023, 178 : 180 - 190
[45] PHASE 2 STUDY OF NIVOLUMAB (ANTI-PROGRAMMED DEATH-1 [PD-1]) IN PATIENTS (PTS) WITH ADVANCED, REFRACTORY SQUAMOUS (SQ) NON-SMALL CELL LUNG CANCER (NSCLC)
Zalcman, G.
Rizvi, N. A.
Lena, H.
Wolf, J.
Mazieres, J.
Antonia, S. J.
Minenza, E.
Planchard, D.
Lestini, B. J.
Ramalingam, S. S.
ANNALS OF ONCOLOGY, 2015, 26
[46] A real-world analysis of second-line treatment option, gemcitabine plus anlotinib and anti-PD1, in advanced pancreatic cancer
Fan, Mengjiao
Ma, Yue
Deng, Guochao
Si, Haiyan
Jia, Ru
Wang, Zhikuan
Dai, Guanghai
PANCREATOLOGY, 2024, 24 (04) : 579 - 583
[47] LONG-TERM SURVIVAL OF IPILIMUMAB-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) TREATED WITH NIVOLUMAB (ANTI-PROGRAMMED DEATH-1; ANTI-PD-1; BMS-936558; ONO-4538) IN A PHASE I TRIAL
Hodi, Stephen
Sznol, Mario
Kluger, Harriet M.
McDermott, David F.
Carvajal, Richard D.
Lawrence, Donald P.
Topalian, Suzanne L.
Atkins, Michael B.
Powderly, John D.
Sharfman, William H.
Puzanov, Igor
Smith, David C.
Leming, Philip D.
Lipson, Evan J.
Taube, Janis M.
Anders, Robert A.
Horak, Christine E.
Kollia, Georgia
Gupta, Ashok
Sosman, Jeffrey A.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 177 - 177
[48] Mortality prediction in real world advanced melanoma patients treated by anti-PD1 within MelBase, a French multicentric prospective cohort
Oriano, B.
Dalle, S.
Mortier, L.
Dutriaux, C.
Dereure, O.
Leccia, M-T.
Dalac, S.
Legoupil, D.
De Quatrebarbes, J.
Montaudie, H.
Arnault, J. P.
Possenti, F. Brunet
Saiag, P.
Maubec, E.
Lesimple, T.
Aubin, F.
Granel-Brocard, F.
Dreno, B.
Porcher, R.
Lebbe, C.
ANNALS OF ONCOLOGY, 2020, 31 : S751 - S751
[49] Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study
van Zeijl, Michiel C. T.
Haanen, John B. A. G.
Wouters, Michel W. J. M.
de Wreede, Liesbeth C.
Jochems, Anouk
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen W.
Piersma, Djura
van Rijn, Rozemarijn S.
Suijkerbuijk, Karijn P. M.
ten Tije, Albert J.
van der Veldt, Astrid A. M.
Vreugdenhil, Gerard
van der Hoeven, Koos J. M.
van den Eertwegh, Alfons J. M.
JOURNAL OF IMMUNOTHERAPY, 2020, 43 (08) : 256 - 264
[50] Effectiveness and safety of anti-PD-1 monotherapy or combination therapy in Chinese advanced gastric cancer: A real-world study
Li, Tao
Liu, Tingting
Zhao, Lei
Liu, Lu
Zheng, Xuan
Wang, Jinliang
Zhang, Fan
Hu, Yi
FRONTIERS IN ONCOLOGY, 2023, 12

← 1 2 3 4 5 →